|
|
News Breaks | | | | March 14, 2013 | | 08:29 EDT |  | ACAD | ACADIA Phase III test results positive, says Roth Capital
Roth Capital believes that a Phase III trial of ACADIA's pimavanserin for psychosis in Parkinson's disease yielded strong efficacy results that support $1B+ potential for the drug. The firm maintains an $11 price target and Buy rating on the shares. | |
|
News For ACAD From The Last 14 Days Check below for free stories on ACAD the last two weeks. |
|
|
| May 15, 2013 | | 08:01 EDT |  | ACAD | ACADIA 8M share Spot Secondary priced at $12.50
 Subscribe for More Information | | | May 14, 2013 | | 16:01 EDT | | ACAD | ACADIA files to sell common stock, no amount given
Subscribe for More Information | | | May 7, 2013 | | 16:04 EDT |  | ACAD | ACADIA expects to use $28M-$32M in cash to fund FY13 operations
Subscribe for More Information | | | 16:03 EDT |  | ACAD | ACADIA reports Q1 EPS (8c), consensus (8c)
Reports Q1 revenue $417,000, consensus $450,000. | |
|
|
|
|
|
|
